A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Fudan University
I-Mab Biopharma US Limited
UNICANCER
Memorial Sloan Kettering Cancer Center
Novartis
Federation Francophone de Cancerologie Digestive
Imugene Limited
Memorial Sloan Kettering Cancer Center
UNICANCER
Ruijin Hospital
Servier
Federation Francophone de Cancerologie Digestive
OHSU Knight Cancer Institute
The First Hospital of Jilin University
Asan Medical Center
Hoosier Cancer Research Network
National Cancer Institute, Naples
Ludwig-Maximilians - University of Munich
GSO Global Clinical Research BV
Fox Chase Cancer Center
UNICANCER
Translational Oncology Research International
AIO-Studien-gGmbH
UNICANCER
University of Florida
Odense University Hospital
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ChineseAMS
The University of Hong Kong
NYU Langone Health
mAbxience Research S.L.
Abramson Cancer Center at Penn Medicine
Dong-A University Hospital
University Health Network, Toronto
University of California, Davis
Peking University
UNC Lineberger Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Huashan Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
M.D. Anderson Cancer Center
Sanofi
Samsung Medical Center
Vanderbilt University
Medical College of Wisconsin
Gustave Roussy, Cancer Campus, Grand Paris
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Duke University